Idaho will receive $208,410 as part of a multi-state $700 million settlement with pharmaceutical distributor Reckitt Benckiser Group following allegations that the company, either directly or through a subsidiary, improperly marketed and promoted the drug Suboxone, Attorney General Lawrence Wasden announced this week.
The settlement resolves allegations from 2010 to 2014, including an allegation that the company took fraudulent steps to delay the entry of generic competition into the market in order to control pricing of Suboxone, including pricing to federal healthcare programs.
The improperly marketed product resulted in improper expenditures of state Medicaid funds, according to a press release from the Attorney General’s Office. Idaho’s portion will be split evenly between the state’s general fund and Medicaid funds.
Suboxone is a drug product approved for use by recovering opioid addicts to avoid or reduce withdrawal symptoms while undergoing detox treatment. Suboxone itself contains an active ingredient, buprenorphine, this is a powerful and addictive opioid.